Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 794-799, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikemoto, M.
Right arrow Articles by Ueda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikemoto, M.
Right arrow Articles by Ueda, K.

Clinical Chemistry, Vol 39, 794-799, Copyright © 1993 by American Association for Clinical Chemistry

Enzyme immunoassay of liver-type arginase and its potential clinical application

M Ikemoto, A Ishida, S Tsunekawa, K Ozawa, Y Kasai, M Totani and K Ueda
College of Medical Technology, Faculty of Medicine, Kyoto University, Japan.

We developed an efficient enzyme-linked immunosorbent assay (ELISA) system for measurement of human liver-type arginase in serum. A conjugate of the Fab' fragment of anti-human liver (recombinant) arginase IgG and horseradish peroxidase was used as the second antibody. This assay is highly specific, sensitive, and reproducible, enabling us to detect arginase at concentrations as low as several micrograms per liter without any prior processing of serum. The reaction is linear up to 200 micrograms/L. The arginase concentration in serum, as determined by this method, increased markedly and temporarily at the time of surgical operation or later injury to the liver. The increase was accompanied or followed by increases in serum concentrations of aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase, suggesting that the arginase emerged from damaged hepatocytes. In view of a limited tissue distribution of liver- type arginase, our ELISA system may be useful in diagnosis of various hepatic disorders as well as follow-up of postoperative conditions of patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Ikemoto, T. Tanaka, Y. Takai, H. Murayama, K. Tanaka, and M. Fujita
New ELISA System for Myeloid-related Protein Complex (MRP8/14) and Its Clinical Significance as a Sensitive Marker for Inflammatory Responses Associated with Transplant Rejection
Clin. Chem., April 1, 2003; 49(4): 594 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Ikemoto, S. Tsunekawa, Y. Toda, and M. Totani
Liver-Type Arginase Is a Highly Sensitive Marker for Hepatocellular Damage in Rats
Clin. Chem., May 1, 2001; 47(5): 946 - 948.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Baggio, F. A. Emig, D. W. Christianson, D. E. Ash, S. Chakder, and S. Rattan
Biochemical and Functional Profile of a Newly Developed Potent and Isozyme-Selective Arginase Inhibitor
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1409 - 1416.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.